Cepheid (NASDAQ:CPHD) Increases Lower End Guidance

During their most recent quarterly report, Cepheid (NASDAQ:CPHD) said they're increasing the lower end of their full year guidance going forward. .

GARP Research commented, "Shares of Cepheid jumped after it reported 2Q10 results. Total revenue grew 21% y/y to $49.6 million, driven by a 41% jump in the clinical segment. This was offset by an expected 35% y/y decline for the Biothreat business, and modest single-digit gains for the Industrial segment...Management raised the lower end of its full year guidance by $5 million to $200-205 million. It considered a modest increase in the top end, but maintained the current level given continued uncertainty in Europe where instrument placements fell 5% y/y during 2Q."

GARP Research maintains a "Buy" on Cepheid, which closed Monday at $21.80, up by $0.50, or 2.37 percent. GARP has a price target of $17 on them.